Omega-3s may reshape breast cancer fats, new study hopes to prove

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient must be ≥18 years of age. * Breast tumor ≥1 cm. * Not currently taking dietary supplements containing fish oil or omega-3 PUFAs. A diet containing fish meat is permitted. * Unilateral and/or bilateral diagnostic breast mammogram and/or ultrasound within 60 days of enrollment. If breast MRI is done per treating physician's discretion, at least one breast imaging modality should be within 60 days of enrollment. * Pathologically proven diagnosis of invasive breast cancer, clinical stage I-III (cT1c-T4, N0-N3, M0). * Concurrent (neoadjuvant) systemic anti-cancer therapy is planned, including but not limited to endocrine therapy, chemotherapy, anti-HER2 therapy, and immunotherapy. * Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2. * Bilateral breast cancer and/or multifocal, multicentric disease is allowed. * Appropriate pretreatment evaluations for protocol entry, including no clinical evidence for distant metastases, based upon the following minimum diagnostic workup: history/physical examination, including breast exam (inspection and palpation of the breasts), within 30 days prior to study entry. * Patients with a prior history of breast cancer will be considered eligible. * Surgical candidacy as determined by the treating physician. * Patient must provide study-specific informed consent prior to study entry or have a legally authorized representative provide consent. Exclusion Criteria: * American Joint Committee on Cancer (AJCC) clinical M1 breast cancer (i.e., with distant metastasis). * Purely noninvasive breast cancer (i.e., ductal carcinoma in situ, lobular carcinoma in situ). * Medical, psychiatric, or other condition that would prevent the patient from receiving the protocol treatment or providing informed consent.